Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MNMD

MNMD - Mind Medicine Stock Price, Fair Value and News

$17.48+0.97 (+5.88%)
Market Closed

10/100

MNMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

MNMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$12.04

Target 3M

$13.55

Target 6M

$12.79

MNMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNMD Price Action

Last 7 days

15.6%

Last 30 days

29.6%

Last 90 days

40.6%

Trailing 12 Months

142%

MNMD RSI Chart

MNMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNMD Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-10.23

Price/Sales (Trailing)

160.21

EV/EBITDA

-21.3

Price/Free Cashflow

-15.11

MNMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$12.04

Target 3M

$13.55

Target 6M

$12.79

MNMD Fundamentals

MNMD Revenue

Revenue (TTM)

10.7M

Rev. Growth (Yr)

-35.5%

Rev. Growth (Qtr)

-18.46%

MNMD Earnings

Earnings (TTM)

-168.4M

Earnings Growth (Yr)

-391.56%

Earnings Growth (Qtr)

-57.39%

MNMD Profitability

EBT Margin

-524.11%

Return on Equity

-128.91%

Return on Assets

-71.06%

Free Cashflow Yield

-6.62%

MNMD Investor Care

Shares Dilution (1Y)

34.33%

Diluted EPS (TTM)

-1.77

MNMD Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202512.3M12.0M10.7M0
20245.9M7.6M9.6M11.6M
20230005.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Mind Medicine

MNMD
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
 CEO
 WEBSITEmindmed.co
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES48

Mind Medicine Frequently Asked Questions

MNMD is the stock ticker symbol of Mind Medicine. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Mind Medicine is 1.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MNMD's fair value in chart for subscribers.

The fair value guage provides a quick view whether MNMD is over valued or under valued. Whether Mind Medicine is cheap or expensive depends on the assumptions which impact Mind Medicine's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNMD.

As of Tue Jan 27 2026, MNMD's PE ratio (Price to Earnings) is -10.23 and Price to Sales (PS) ratio is 160.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNMD PE ratio will change depending on the future growth rate expectations of investors.